Foresight for Healthcare Founders: Reading Where Care Delivery Is Actually Heading
By the time a shift in healthcare is common knowledge — something every investor deck references, every competitor has already repositioned around — the advantage of seeing it early is already gone. Healthcare founders don't need to predict the future. They need a disciplined way to read the signals that are already visible today, before regulatory guidance, reimbursement policy, and market consensus catch up to where care delivery is actually heading. That's what foresight practice is for, and it's a different skill than the strategic planning most founders already do.
What Foresight Actually Means (Not Prediction)
Foresight practice, the discipline I trained in as a Certified Foresight Practitioner, isn't about forecasting a single confident outcome. It's about scanning for weak signals — early, ambiguous indicators that haven't yet become obvious — and understanding the driving forces behind them well enough to hold several plausible futures at once, rather than betting everything on one. A forecaster says "telehealth reimbursement will be permanent by 2028." A foresight practitioner says "here's the range of plausible reimbursement paths, here's what would make each one more or less likely, and here's how to build a company that isn't destroyed by being wrong about which one happens." That distinction matters enormously in a sector where being wrong about a regulatory assumption doesn't just hurt growth — it can end the company.
Why Healthcare's Consensus Lag Is Especially Wide
Every industry has some gap between "what's actually happening" and "what the market has priced in," but healthcare's gap runs wider and longer than most. Regulatory guidance takes years to formalize. Reimbursement policy moves on its own multi-year cycle, often behind the clinical practice it's supposed to govern. Clinical validation itself takes years before an approach earns broad trust. That lag is exactly what creates the opportunity: a founder who reads the early signals correctly can build toward where care delivery, diagnostics, or reimbursement are actually heading, while competitors are still building for where the market currently assumes things stand.
Three Real Signals Worth Reading Correctly Right Now
These aren't predictions — they're current, verifiable signals, and the point of this section is less "here's what's coming" and more "here's how to read something like this correctly when you see it."
1. CMS is signaling a shift in mechanism, not just more of the same
In late 2025, CMS ended several existing value-based care models ahead of schedule and announced a new payment model built specifically around technology-enabled care. The naive read is "value-based care keeps growing." The more accurate read is that the mechanism itself is changing shape — which matters differently depending on whether your company was built for the old models or the new one.
2. FDA is thinking out loud about generative AI before the rules exist
The FDA doesn't usually publish a public discussion paper and ask for feedback before it has a regulatory position — but that's exactly what it did with generative AI-enabled medical devices. Reading that discussion paper now, months or years before a final framework exists, is a very different position than waiting for the eventual rule and reacting to it.
3. A reimbursement "extension" is a signal, not a settled outcome
Congress recently extended Medicare telehealth flexibilities for two more years. It's tempting to read that as "telehealth reimbursement is now secure." A foresight read holds both plausible futures at once — permanence and lapse — and asks what a business model needs to survive either one, rather than quietly building as if the more comfortable outcome is guaranteed.
A Simple Foresight Exercise Founders Can Run Themselves
This doesn't require formal training to start — a version of it is close to what I walk through with founders directly in founder consulting conversations.
- Name the driving forces actually shaping your category — regulatory posture, reimbursement mechanics, workforce capacity, technology cost curves — not just the trend everyone's already talking about.
- Collect weak signals tied to those forces: proposed rules, discussion papers, pilot program results, workforce data — the kind of source, not opinion pieces about the source.
- Build at least two plausible futures, not one. If your whole plan only works in the single future you're hoping for, that's a fragility problem, not a strategy.
- Ask what would falsify each future — what specific, observable event would tell you that a given path is becoming more or less likely, so you're watching for evidence rather than just waiting to be right.
Foresight Mistakes That Look Like Insight
- Treating one compelling signal as if it were already the whole trend
- Mistaking personal conviction — "I just believe this is where things are going" — for an actual observed signal
- Reading a policy extension, a pilot program, or a discussion paper as a finished outcome rather than a data point
- Building a plan that only survives in the single future you're hoping happens
- Waiting for a trend to become obvious before acting on it — at which point the advantage of seeing it early is already gone
What This Looks Like in Practice
This is the same lens I bring to evaluating healthcare companies directly, not just writing about the method. Reading where clinical validation, regulatory posture, and investor appetite were actually heading — rather than where the consensus already stood — is part of what shaped my own healthcare investments, including backing Radix Motion, Circularis, and Volumetric Biotechnologies before each reached the outcome it eventually did. If you're trying to figure out whether your own roadmap is built for where healthcare is actually going, or just for where it currently appears to be, that's the conversation worth having.
Trying to pressure-test your own read on where your category is heading? Schedule a free consult — you'll leave with a sharper sense of which signals are worth watching and which are noise, even if we never work together beyond that conversation.
Foresight for Healthcare Founders FAQs
Question: What is foresight practice, and how is it different from forecasting?
Answer: Forecasting tries to predict a single, specific outcome. Foresight practice scans for early, ambiguous signals and holds multiple plausible futures at once, asking what would make each more or less likely rather than betting everything on one predicted outcome. It’s a discipline for staying resilient to being wrong, not a claim to being right.
Question: Why does healthcare need foresight more than other industries?
Answer: Healthcare has an unusually wide gap between what’s actually happening in care delivery and technology, and what regulatory guidance, reimbursement policy, and market consensus have caught up to. Regulatory and reimbursement cycles often run years behind clinical practice, which creates real opportunity for founders who can read early signals correctly, and real risk for those who build only for where the market currently assumes things stand.
Question: What’s an example of a real healthcare signal worth watching right now?
Answer: CMS ending several value-based care models early in 2025 while launching a new payment model built specifically around technology-enabled care is a good example — the naive read is “more value-based care,” but the more accurate read is that the underlying mechanism is changing shape, which matters differently depending on which model a company was built around.
Question: How can a founder avoid mistaking their own bias for a genuine signal?
Answer: Ground every signal in a verifiable source — a proposed rule, a discussion paper, pilot data — rather than an opinion or a personal conviction about where things should go. Then ask what would falsify it: a specific, observable event that would tell you the signal is weakening, not just evidence that would confirm what you already wanted to believe.
Dr. Alan Jacobson, Psy.D., MBA is a Certified Foresight Practitioner (TFSX) and licensed psychologist with 25+ years of experience, specializing in the psychology of high performance. He advises and invests in founders across four industries — Healthcare, Housing, Energy, and Independent Film — pairing that clinical training with hands-on board, investor, and producer experience.